Table 2.
Clinical characteristics of non-LT and LT cases receiving DAA therapy.
| Case | Age | Sex | LC or CH | HCV RNA (pre) (LogIU/ml) | Tacrolimus blood levels (ng/ml) | IL28B genotype | History of HCC | Previous DAA exposure | Reason for non-SVR |
|---|---|---|---|---|---|---|---|---|---|
| Non-LT #1 | 75 | F | LC | 6.6 | – | NA | No | – | AE |
| Non-LT #2 | 61 | F | CH | 6.6 | – | NA | No | TRV | VBT |
| Non-LT #3 | 63 | F | LC | 5.5 | – | NA | No | SMV | AE |
| Non-LT #4 | 78 | M | CH | 5.4 | – | NA | No | – | VBT |
| LT #1 | 63 | M | CH | 7.8 | 3.9 | TT | No | SMV | NR |
| LT #2 | 63 | M | CH | 6.8 | 4.9 | TG | No | SMV | VBT |
| LT #3 | 64 | M | CH | 6.9 | 9.1 | TT | No | SMV | NR |
| LT #4 | 68 | M | CH | 7.6 | 6 | TT | No | SMV | NR |
LT liver transplantation, DAA direct acting antivirals, M male, F female, LC liver cirrhosis, CH chronic hepatitis, SMV simeprevir, TRV telaprevir, SVR sustained virological response, VBT viral breakthrough, NR non-responder, AE adverse event, – not detectable, NA not available.